24479669 23092280 29593050 25119469 22933279 23667257 30541842 24644289 24390333 22284360 23602046 25707797 24478426 31110236 24963694 33253374 25900654 27334589 - Search Results

Year	Number of Results
2012	2
2013	3
2014	6
2015	2
2016	1
2018	1
2019	2
2021	1
2023	0

1

Identification of nitrated immunoglobulin variable regions in the HIV-infected human brain: implications in HIV infection and immune response.

Uzasci L, Bianchet MA, Cotter RJ, Nath A. Uzasci L, et al. J Proteome Res. 2014 Mar 7;13(3):1614-23. doi: 10.1021/pr401117m. Epub 2014 Jan 30. J Proteome Res. 2014. PMID: 24479669 Free PMC article.

2

Inhibitors of HIV-1 entry.

Micewicz ED, Ruchala P. Micewicz ED, et al. Curr Pharm Des. 2013;19(10):1784-99. doi: 10.2174/1381612811319100003. Curr Pharm Des. 2013. PMID: 23092280 Review.

3

eCD4-Ig Variants That More Potently Neutralize HIV-1.

Fetzer I, Gardner MR, Davis-Gardner ME, Prasad NR, Alfant B, Weber JA, Farzan M. Fetzer I, et al. J Virol. 2018 May 29;92(12):e02011-17. doi: 10.1128/JVI.02011-17. Print 2018 Jun 15. J Virol. 2018. PMID: 29593050 Free PMC article.

4

Targeting strategies for delivery of anti-HIV drugs.

Ramana LN, Anand AR, Sethuraman S, Krishnan UM. Ramana LN, et al. J Control Release. 2014 Oct 28;192:271-83. doi: 10.1016/j.jconrel.2014.08.003. Epub 2014 Aug 10. J Control Release. 2014. PMID: 25119469 Free PMC article. Review.

5

Enhanced recognition and neutralization of HIV-1 by antibody-derived CCR5-mimetic peptide variants.

Chiang JJ, Gardner MR, Quinlan BD, Dorfman T, Choe H, Farzan M. Chiang JJ, et al. J Virol. 2012 Nov;86(22):12417-21. doi: 10.1128/JVI.00967-12. Epub 2012 Aug 29. J Virol. 2012. PMID: 22933279 Free PMC article.

6

Direct expression and validation of phage-selected peptide variants in mammalian cells.

Quinlan BD, Gardner MR, Joshi VR, Chiang JJ, Farzan M. Quinlan BD, et al. J Biol Chem. 2013 Jun 28;288(26):18803-10. doi: 10.1074/jbc.M113.452839. Epub 2013 May 10. J Biol Chem. 2013. PMID: 23667257 Free PMC article.

7

A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.

Fetzer I, Davis-Gardner ME, Gardner MR, Alfant B, Weber JA, Prasad NR, Zhou AS, Farzan M. Fetzer I, et al. J Virol. 2019 Feb 19;93(5):e01653-18. doi: 10.1128/JVI.01653-18. Print 2019 Mar 1. J Virol. 2019. PMID: 30541842 Free PMC article.

8

The N-terminal region of the atypical chemokine receptor ACKR2 is a key determinant of ligand binding.

Hewit KD, Fraser A, Nibbs RJ, Graham GJ. Hewit KD, et al. J Biol Chem. 2014 May 2;289(18):12330-42. doi: 10.1074/jbc.M113.534545. Epub 2014 Mar 18. J Biol Chem. 2014. PMID: 24644289 Free PMC article.

9

A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120.

Quinlan BD, Joshi VR, Gardner MR, Ebrahimi KH, Farzan M. Quinlan BD, et al. J Virol. 2014 Mar;88(6):3353-8. doi: 10.1128/JVI.03800-13. Epub 2014 Jan 3. J Virol. 2014. PMID: 24390333 Free PMC article.

10

A synthetic heparan sulfate-mimetic peptide conjugated to a mini CD4 displays very high anti- HIV-1 activity independently of coreceptor usage.

Connell BJ, Baleux F, Coic YM, Clayette P, Bonnaffé D, Lortat-Jacob H. Connell BJ, et al. Chem Biol. 2012 Jan 27;19(1):131-9. doi: 10.1016/j.chembiol.2011.12.009. Chem Biol. 2012. PMID: 22284360

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results